Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nutriband Inc. - Common Stock (NQ:NTRB)

7.572 -0.148 (-1.92%)
Streaming Delayed Price Updated: 2:54 PM EDT, Jun 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nutriband Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Price Target Raised to $15 Following AVERSA Fentanyl Manufacturing Milestone
Via Investor Brand Network
Nutriband Inc. (NASDAQ: NTRB) Reimagining Drug Safety Through Scalable Innovation
Via Investor Brand Network
Topics Death Intellectual Property
Exposures Death Intellectual Property
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Advances Aversa Fentanyl with Kindeva to Commercial Manufacturing Scale
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
NUTRIBAND AND KINDEVA COMPLETE COMMERCIAL MANUFACTURING PROCESS SCALE-UP FOR AVERSA™ FENTANYL ABUSE DETERRENT FENTANYL PATCH
Nutriband and Kindeva have completed commercial manufacturing process scale-up for its lead product Aversa™ Fentanyl, an abuse-deterrent fentanyl patch. Nutriband is partnering with Kindeva to develop... 
Via FinancialNewsMedia
Exposures Product Safety
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:PFE),(NASDAQ:COLL),(NYSE:TEVA),(NYSE:EBS) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Exposures Death
Nutriband and Kindeva Complete Commercial Manufacturing Process Scale-up for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch
From Nutriband Inc.
Via GlobeNewswire
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
From FN Media Group LLC
Via GlobeNewswire
Nutriband Inc. (NASDAQ: NTRB) Reports Double-Digit Revenue Increase, Continued Progress on AVERSA Fentanyl Development
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Secures U.S. Patent for Abuse-Deterrent Transdermal Technology
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology
From Nutriband Inc.
Via GlobeNewswire
Nutriband Inc. (NASDAQ: NTRB) Advances Abuse-Deterrent Buprenorphine Therapy with AVERSA Technology
Via Investor Brand Network
Nutriband Inc. (NASDAQ: NTRB): A Relentless Mission Rooted in Purpose, Innovation, and Shareholder Value
Via Investor Brand Network
Topics Initial Public Offering
Exposures Securities Market
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) to Present at Noble Capital Markets Emerging Growth Virtual Conference
Via Investor Brand Network
Nutriband Inc. to present at the 2025 Noble Capital Markets Virtual Equity Conference
From Nutriband Inc.
Via GlobeNewswire
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Posts Record Q1 Revenue, Advances AVERSA Fentanyl Development
Via Investor Brand Network
Nutriband Inc. Quarterly Report Highlights Record Revenue for Q1, 2025 up 63% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl
From Nutriband Inc.
Via GlobeNewswire
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) CEO Highlights Transdermal Pain Solution on BioMedWire Podcast
Via Investor Brand Network
Nutriband Inc. (NASDAQ: NTRB) Charts Path to Commercialization
Via Investor Brand Network
BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Strengthens Pharma Footprint Through Key Alliances
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
Nutriband Inc. (NASDAQ: NTRB) Pioneers Innovative Approach to Opioid Crisis with Game-Changing Transdermal Patch
Via Investor Brand Network
Nutriband Inc. (NASDAQ: NTRB) Innovating Abuse-Deterrent Drug Delivery in a Shifting Opioid Landscape
Via Investor Brand Network
Exposures Product Safety
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) CEO Issues Shareholder Letter Highlighting 2024 Milestones and 2025 Commercialization Goals
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Nutriband Inc. (NASDAQ: NTRB) Leadership Team: Driving Innovation and Shaping the Future of Global Healthcare
Via Investor Brand Network
Nutriband CEO Publishes Letter to Shareholders
From Nutriband Inc.
Via GlobeNewswire
Nutriband Inc. (NASDAQ: NTRB) Solution To Fentanyl Abuse Could Translate To $200 Million In Peak Revenue
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property
Nutriband Inc (NASDAQ: NTRB) Solution To Fentanyl Abuse Could Translate To $200 Million In Peak Revenue
Nutriband Inc (NASDAQ: NTRB) Solution To Fentanyl Abuse Could Translate To $200 Million In Peak Revenue 
Via News Direct
Topics Intellectual Property
Exposures Intellectual Property
BioMedNewsBreaks — Why Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Nutriband Inc. (NASDAQ: NTRB): Building a Moat Around Abuse-Deterrent Drug Delivery
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) CEO Named EY Entrepreneur of the Year 2025 Finalist in Established Category
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.